Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Adults in Africa

NCT02485301 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02485301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02485301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Adults in Africa
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
July 15, 2015
Completion date
December 23, 2016
Enrollment
3,024 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

virus diseases